Josep Llovet

Josep Llovet co-developed the Barcelona Clinic Liver Cancer (BCLC) staging and treatment algorithm that is the most widely used HCC management framework globally, and led the SHARP trial demonstrating sorafenib as the first effective systemic therapy for advanced HCC. His molecular profiling of HCC has identified actionable targets and prognostic subclasses, informing adjuvant and systemic therapy development. He continues to investigate novel adjuvant immunotherapy approaches including atezolizumab/bevacizumab and pembrolizumab in resected HCC. Llovet is among the most cited researchers in liver cancer worldwide.